<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-132354" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Relapsed and Refractory Follicular Lymphoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Daulath</given-names>
          </name>
          <aff>Stormont Vail Healthcare</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Annapoorna</given-names>
          </name>
          <aff>Kansas City School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mukkamalla</surname>
            <given-names>Shiva Kumar R.</given-names>
          </name>
          <aff>Presbyterian Healthcare Services</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Daulath Singh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Annapoorna Singh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shiva Kumar Mukkamalla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>15</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-132354.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Follicular lymphoma is the second most common subtype of non-Hodgkin lymphoma (NHL) and the most common among clinically indolent NHLs. It has a diverse clinical trajectory and is a heterogeneous disease. This lymphoma is derived from germinal center B cells, centrocytes, and centroblasts. The growth pattern of this lymphoma is almost always nodular with a follicular pattern. Most people with this disease will have a clinically indolent course, needing only intermittent therapy over decades. Asymptomatic relapsed cases can be observed and monitored closely for symptom development and do not need immediate treatment. The treatment of late relapsed cases depends on several factors, such as comorbidities, disease burden, and performance status. This activity covers the diagnosis and management of follicular lymphoma.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the etiology and clinical presentation of relapsed and refractory follicular lymphoma.</p></list-item><list-item><p>Assess&#x000a0;the investigations of relapsed and refractory follicular lymphoma.</p></list-item><list-item><p>Evaluate&#x000a0;the treatment options for relapsed and refractory follicular lymphoma.</p></list-item><list-item><p>Communicate&#x000a0;the importance of a multidisciplinary team approach in treating relapsed and refractory follicular lymphoma.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=132354&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=132354">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-132354.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Follicular lymphoma is an incurable B-cell neoplasm characterized by substantial biochemical and clinical heterogeneity. As the most prevalent indolent lymphoma and the second most common non-Hodgkin lymphoma (NHL), it has a relapsing and remitting course with the potential to progress to aggressive disease. About 20% of the patients with follicular lymphoma develop disease progression within the first&#x000a0;2 years of chemotherapy, with an overall 5-year survival rate of 50%.&#x000a0;The duration of remission appears to have prognostic significance, as those who relapse within 24 months of chemotherapy or 12 months of rituximab are reported to have a poor prognosis.<xref ref-type="bibr" rid="article-132354.r1">[1]</xref><xref ref-type="bibr" rid="article-132354.r2">[2]</xref>&#x000a0;While anti-CD20-based chemoimmunotherapy remains an essential standard of treatment, more biologically active agents are increasingly used. This review explores diagnostic and therapeutic strategies for relapsed/refractory follicular lymphoma.</p>
      </sec>
      <sec id="article-132354.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Follicular lymphoma is believed to originate from germinal center B-cells, including both centrocytes and centroblasts.<xref ref-type="bibr" rid="article-132354.r3">[3]</xref>&#x000a0;Although the pathophysiology of follicular lymphoma is not well understood, follicular lymphoma is defined by the translocation t(14;18), which occurs in 90% of the cases. This translocation results in the juxtaposition of the B-cell leukemia/lymphoma 2 (BCL2) gene with regulatory elements of the immunoglobulin heavy chain gene (IGH) as a consequence of aberrant V(D)J recombination. This leads to an increase in Bcl-2 protein expression and cell survival.<xref ref-type="bibr" rid="article-132354.r4">[4]</xref>&#x000a0;Early gene mutations encoding chromatin-modifying proteins have been a significant discovery in recent years.<xref ref-type="bibr" rid="article-132354.r5">[5]</xref><xref ref-type="bibr" rid="article-132354.r6">[6]</xref>&#x000a0;These 'epimutations' are a second distinguishing characteristic of follicular lymphoma. These include <italic toggle="yes">N</italic>-methyltransferase 2D (KMT2D), histone acetylases, CREBBP, enhancer of zeste homologue 2 (EZH2), and&#x000a0;E1A binding protein P300 (EP300).<xref ref-type="bibr" rid="article-132354.r5">[5]</xref><xref ref-type="bibr" rid="article-132354.r7">[7]</xref><xref ref-type="bibr" rid="article-132354.r8">[8]</xref><xref ref-type="bibr" rid="article-132354.r9">[9]</xref>&#x000a0;These mutations accelerate the proliferation of the germinal center, inhibit cellular differentiation, and restrict immunological invasion. These mutations, together with the BCL2 translocation, are early events happening in a common progenitor cell.</p>
      </sec>
      <sec id="article-132354.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Follicular lymphoma affects individuals of all races and geographic regions. Follicular lymphoma accounts for roughly 35 percent of NHLs in the United States, with an estimated incidence of 3.18 cases per 100,000 individuals. In contrast, the estimated incidence in Europe is 2.18 cases per 100,000 people per year.<xref ref-type="bibr" rid="article-132354.r10">[10]</xref>&#x000a0;The incidence in White people is more than twice as high as in Black population and Asian groups.<xref ref-type="bibr" rid="article-132354.r11">[11]</xref><xref ref-type="bibr" rid="article-132354.r12">[12]</xref><xref ref-type="bibr" rid="article-132354.r13">[13]</xref>&#x000a0;Follicular lymphoma seems less prevalent in Central and South America, contributing to around 20% of NHL.<xref ref-type="bibr" rid="article-132354.r14">[14]</xref>&#x000a0;There is no significant gender variation. The median age at diagnosis is 65 years.<xref ref-type="bibr" rid="article-132354.r14">[14]</xref><xref ref-type="bibr" rid="article-132354.r15">[15]</xref>&#x000a0;Incidence rises with age; middle-aged and elderly patients are most often affected.&#x000a0;Follicular lymphoma seldom occurs in adolescents or children.<xref ref-type="bibr" rid="article-132354.r16">[16]</xref><xref ref-type="bibr" rid="article-132354.r17">[17]</xref><xref ref-type="bibr" rid="article-132354.r18">[18]</xref></p>
      </sec>
      <sec id="article-132354.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The nodular development pattern of follicular lymphoma, which mirrors the typical germinal centers of secondary lymphoid follicles and obliterates the typical lymphoid architecture, is&#x000a0;1 of the most conspicuous morphologic characteristics of follicular lymphoma. In contrast to normal reactive follicles, the nodules in follicular lymphoma are often densely packed and of varying size and form. The neoplastic follicles may be present throughout the tumor tissue or just in a section, with a diffuse component comprising the remainder of the tumor. Centrocytes are small cleaved follicular cells with elongated or cleaved nuclei, inconspicuous nucleoli, and scant pale cytoplasm. Centroblasts are noncleaved follicular center cells with round or oval nuclei, vesicular chromatin, often multiple peripheral nucleoli, and a narrow rim of basophilic cytoplasm. Centrocytes typically predominate in follicular lymphoma, and centroblasts are usually in the minority. WHO classifies follicular lymphoma into grades 1,2 and 3a/3b based on the cell counting method of centroblasts.<xref ref-type="bibr" rid="article-132354.r19">[19]</xref></p>
        <p>Malignant follicles include T-cells and densely structured networks of follicular dendritic cells, similar to those in normal germinal centers. The polarization of normal reactive germinal centers into dark zones rich in centroblasts and light zones rich in centrocytes is absent in neoplastic follicles. Interfollicular spaces in follicular lymphomas may house normal T-cells and a varied percentage of malignant cells. Neoplastic follicles generally have a smaller Ki-67+ proportion (a sign of proliferation) than reactive follicles. The number of mitotic figures and cells that are positive for the Ki-67 marker rises with increasing grade. The immunophenotype of follicular lymphoma is confirmed by flow cytometry or immunohistochemistry. The tumor cells have surface immunoglobulin expression, with 50-60% of cells expressing IgM. Either kappa or lambda light chains are present. Cells are positive for B-cell antigens, including CD19, CD20, CD79a, and CD10. No expression of CD5, CD43, and CD11c is noted.<xref ref-type="bibr" rid="article-132354.r20">[20]</xref><xref ref-type="bibr" rid="article-132354.r21">[21]</xref>&#x000a0;CD23 expression is variable. Cells are also positive for Bcl-2 protein expression.<xref ref-type="bibr" rid="article-132354.r22">[22]</xref><xref ref-type="bibr" rid="article-132354.r23">[23]</xref></p>
      </sec>
      <sec id="article-132354.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Most patients with follicular lymphoma present with painless peripheral lymphadenopathy.&#x000a0;The adenopathy commonly waxes and wanes spontaneously but does not altogether disappear.<xref ref-type="bibr" rid="article-132354.r24">[24]</xref>&#x000a0;Some patients present with relatively asymptomatic large abdominal masses, with or without evidence of gastrointestinal or urinary tract obstruction. Follicular lymphoma evaluation can show the involvement of the spleen, liver, or bone marrow.<xref ref-type="bibr" rid="article-132354.r25">[25]</xref>&#x000a0;Only about 20 percent of patients have B symptoms (fevers, night sweats, or unintentional weight loss).<xref ref-type="bibr" rid="article-132354.r24">[24]</xref>&#x000a0;Patients are evaluated at regular intervals after completion of the initial therapy to monitor for treatment complications and progression. Patients are assessed with detailed history and physical examination, complete blood count, comprehensive metabolic panel, and lactate dehydrogenase. On physical examination, a rapid rise in the size and number of lymph nodes, or the development of B symptoms such as night sweats, fevers, weight loss, and fatigue, generally indicate relapsed disease.</p>
      </sec>
      <sec id="article-132354.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Imaging with positron emission tomography/computed tomography (PET/CT) scans can provide information about the disease's new baseline, the anatomic regions involved, and their metabolic activity. Biopsy should target the lymph node with the highest metabolic activity. Bone marrow biopsy is reserved for individuals with unexplained cytopenias. Follicular lymphoma may evolve into a more aggressive and higher grade of lymphoma, such as diffuse large B-cell lymphoma. Hence, a biopsy is essential to diagnose this transformation at relapse.</p>
      </sec>
      <sec id="article-132354.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p><bold>Early relapse</bold>: Early treatment failure is defined as the progression of follicular lymphoma within 24 months (POD24) of the initiation of immunochemotherapy with R-CHOP&#x000a0;(cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab), BR (bendamustine plus rituximab), R-CVP (cyclophosphamide, vincristine, and prednisone) or within 12 months (POD12) of single-agent rituximab treatment. Asymptomatic relapsed follicular lymphoma cases do not need immediate treatment and should be monitored regularly for symptom development.&#x000a0;</p>
        <p>The prognostic value of POD24 was validated in a pooled analysis of 13 international clinical trials that included &#x0003e;5000 patients treated initially with chemotherapy (49 percent), chemoimmunotherapy (46 percent), or rituximab alone (5 percent). A 24-month landmark analysis was used to report subsequent overall survival (OS) according to disease status 24 months after initial treatment. After adjustment for gender and stratification per&#x000a0;performance status and follicular lymphoma international prognostic index (FLIPI), POD24 was associated with worse subsequent OS (estimated 5-year OS 71 versus 94 percent; HR 3.03, 95% CI 2.65-3.47). This prognostic impact was seen in all treatment groups.<xref ref-type="bibr" rid="article-132354.r26">[26]</xref>&#x000a0;In early relapse cases, a biopsy is needed to confirm relapse and exclude aggressive histology or transformation.&#x000a0;</p>
        <p>Immunotherapy or chemoimmunotherapy alone is not likely to result in long-term survival for patients who experience early treatment failure.&#x000a0;Patients who have a complete response to chemoimmunotherapy [bendamustine plus obinutuzumab (BG) or obinutuzumab plus CHOP (G-CHOP)] may benefit from autologous hematopoietic stem cell transplantation (HSCT) as it improves survival. Individuals who have not achieved a complete response may be good candidates for chimeric antigen receptor T-cell (CAR-T) treatment or&#x000a0;1 of the novel agents discussed below. For patients who are not HSCT candidates, using novel agents such as lenalidomide, copanlisib, and tazemetostat is recommended.&#x000a0;Several retrospective analyses suggest autologous HSCT improves survival when compared with chemoimmunotherapy alone.<xref ref-type="bibr" rid="article-132354.r27">[27]</xref><xref ref-type="bibr" rid="article-132354.r28">[28]</xref><xref ref-type="bibr" rid="article-132354.r29">[29]</xref>&#x000a0;High-dose chemotherapies with autologous HSCT (hematologic rescue) and nonmyeloablative or reduced-intensity allogeneic HSCT have been used to treat follicular&#x000a0;lymphoma.&#x000a0;</p>
        <p>CAR-T therapy is an option for patients with multiply relapsed follicular lymphomas.&#x000a0;CAR-T cells are created from the patient's T-lymphocytes that have been genetically modified (transfected) with a gene encoding a CAR to direct the T-cells against the lymphoma cells. The T-cells are genetically changed ex vivo, multiplied in a production facility, and then reinfused into the patient as a form of treatment. Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-directed CAR-T therapies that are approved by the Food and Drug Administration (FDA).<xref ref-type="bibr" rid="article-132354.r30">[30]</xref><xref ref-type="bibr" rid="article-132354.r31">[31]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Axi-cel</bold>&#x000a0;&#x02013; Among the 86 patients with follicular lymphoma treated with axi-cel in ZUMA-5, the overall response rate (ORR) was 94% (79% complete remission [CR], 15% partial remission [PR]) with a median time to first response of&#x000a0;1 month. Response rates were similar in patients with and without high-risk features, including early treatment failure. The estimated progression-free survival (PFS) at 18 months was 73% (95% CI 64-80 percent), and the estimated OS at 18 months was 92% (95% CI 85-95 percent). Cytokine release syndrome (CRS) of any grade was reported in 78 percent (6 percent &#x02265;grade 3). Management included tocilizumab (50 percent), corticosteroids (18 percent), and vasopressors (5 percent).<xref ref-type="bibr" rid="article-132354.r30">[30]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Tisa-cel</bold>&#x000a0;&#x02013; Among the 90 patients with follicular lymphoma treated with tisa-cel, the ORR was 86 percent (69 percent CR, 17 percent PR) with a median time to first response of 2.9 months. The median duration of response was not reached, with a median follow-up of 9.1 months. The estimated PFS at 12 months was 71 percent (95% CI 58-80 percent). CRS of any grade was reported in 53 percent, all less than grade 3.<xref ref-type="bibr" rid="article-132354.r31">[31]</xref></p>
          </list-item>
        </list>
        <p>CAR-T therapy is associated with significant side effects, such as catastrophic neurologic events and CRS, a severe systemic reaction (e.g., high fever, flu-like symptoms, hypotension, mental state abnormalities) due to the activation and proliferation of CAR-T cells.</p>
        <p><bold>Late relapse</bold>: Relapses that occur more than 24 months or 12 months after the first chemoimmunotherapy or single-agent rituximab, respectively, are associated with a clinically indolent course, needing intermittent treatment across the course of the disease over decades and survival rates that are comparable to those seen in the general population.<xref ref-type="bibr" rid="article-132354.r1">[1]</xref>&#x000a0;The current conventional treatment often leads to full or partial remissions, but it is not curative. Treatment goals include symptom relief, restoration of normal cell counts, and enhancement of quality of life. Similar to early relapse, asymptomatic late-relapsed cases usually do not need immediate treatment and are usually monitored for symptom development.&#x000a0;For symptomatic late relapsed cases, options include anti-CD20 monoclonal antibodies, chemoimmunotherapy, or novel agents.&#x000a0;</p>
        <p>Treatment choice is based on several factors, including the patient's response to prior therapy, the existence or absence of certain mutations, the patient's performance status, and the presence of comorbidities that may influence the patient's tolerance to systemic therapy.&#x000a0;Rituximab monotherapy is recommended for patients with comorbidities that deem them poor candidates for chemotherapy and those with advanced tumor burden and good past treatment response to single-agent rituximab owing to its low toxicity profile. The dosing schedule of the rituximab can be either IV 375 mg/m per week for&#x000a0;4 doses<xref ref-type="bibr" rid="article-132354.r32">[32]</xref>&#x000a0;or IV 375 mg/m per week for&#x000a0;4 weeks, followed by additional doses administered every&#x000a0;2 months for&#x000a0;2 years as maintenance.<xref ref-type="bibr" rid="article-132354.r33">[33]</xref>&#x000a0;When compared with ofatumumab, rituximab was at least as effective in terms of overall response rate (ORR, 66 versus 50 percent) and PFS (median 21 versus 16 months)&#x000a0;in randomized phase III trial of patients with rituximab-sensitive indolent NHL (predominant follicular lymphoma) relapsed greater than&#x000a0;6 months after single agent rituximab or a rituximab-containing regimen.<xref ref-type="bibr" rid="article-132354.r34">[34]</xref>&#x000a0;Patients who received extended rituximab regimen after nonprogression on the initial&#x000a0;4 weekly regimens had superior event-free survival but a similar OS.<xref ref-type="bibr" rid="article-132354.r35">[35]</xref></p>
        <p>Chemoimmunotherapy options include anti-CD20 monoclonal antibodies (rituximab or obinutuzumab) with CHOP, bendamustine, or lenalidomide.&#x000a0;Combining bendamustine with obinutuzumab or rituximab is preferred for patients previously receiving CVP or CHOP. Bendamustine can be used again in patients who had prolonged remission with the same treatment. In the GADOLIN trial,&#x000a0;6 cycles of bendamustine plus obinutuzumab followed by maintenance obinutuzumab versus&#x000a0;6 cycles of bendamustine alone showed superior PFS and OS.<xref ref-type="bibr" rid="article-132354.r36">[36]</xref>&#x000a0;CHOP with either rituximab or obinutuzumab is preferred in patients who received bendamustine-based therapy. Maintenance with anti-CD20 monoclonal antibody improves PFS but no OS. If offered, it is usually given every&#x000a0;2 months for 2 years. If the lymphoma relapses while on maintenance therapy, then continued maintenance with anti-CD20 is not advisable. However, patients on rituximab maintenance might be eligible for obinutuzumab maintenance. A meta-analysis of&#x000a0;9 trials including 2586 adult patients with follicular lymphoma reported that patients who received maintenance rituximab&#x000a0;demonstrated superior rates of OS for patients with the relapsed disease (HR 0.72, 95% CI 0.57-0.91) but not for those with previously untreated follicular lymphoma (HR 0.86, 95% CI 0.60-1.25) or if the patients were eligible for rituximab&#x000a0;retreatment at disease progression (HR 0.86, 95% CI 0.49-1.49).<xref ref-type="bibr" rid="article-132354.r37">[37]</xref></p>
        <p>First-relapse patients with EZH2 mutations and second-relapse patients without EZH2 mutations are both eligible for tazemetostat. About 20% of follicular lymphoma cases are associated with EZH2 mutations, and such patients have a better prognosis and a better response to therapy overall. Tazemetostat&#x000a0;is approved as a single agent for treating patients with relapsed or refractory&#x000a0;EZH2&#x000a0;mutation-positive follicular lymphoma who have received at least&#x000a0;2 prior systemic therapies. Tazemetostat is also approved for patients with relapsed or refractory follicular lymphoma with no satisfactory alternative treatment options and no EZH2 mutations. Approval was based on phase 1/2 trial - among patients with EZH2 mutated follicular lymphoma, ORR was 69% with 13% CR and 56% PR, and median PFS was 14 months. Among patients with EZH2 wild-type follicular lymphoma, ORR was 35%, 4% CR, and median PFS was 11 months. The most common side effects of tazemetostat include infections, fatigue, muscle pain, nausea, and abdominal pain.<xref ref-type="bibr" rid="article-132354.r38">[38]</xref>.&#x000a0;Lenalidomide with rituximab or obinutuzumab are other alternatives. AUGMENT trial evaluated the addition of lenalidomide to rituximab, resulting in improved PFS (39 months versus 14 months); OS data was immature. Patients on lenalidomide plus rituximab had higher rates of infections, cutaneous reactions, and cytopenia.<xref ref-type="bibr" rid="article-132354.r39">[39]</xref></p>
        <p>After&#x000a0;2 prior systemic therapies, the phosphoinositide 3'-kinase (PI3K) inhibitor copanlisib is approved by the FDA for use in relapsed or refractory follicular lymphoma. CHRONOS-3 trial randomly assigned 458 patients with relapsed clinically indolent non-Hodgkin lymphoma (275 with follicular lymphoma) in a 2:1 ratio to receive copanlisib plus rituximab versus placebo plus rituximab.<xref ref-type="bibr" rid="article-132354.r40">[40]</xref>&#x000a0;After a median follow-up of 19 months, copanlisib plus rituximab improved PFS (median 22 versus 14 months, HR 0.52, 95% CI 0.39-0.69). The addition of copanlisib increased serious treatment-emergent adverse events (47 versus 18 percent) with higher rates of grade 3/4 hyperglycemia and hypertension. High-dose chemotherapy with autologous HSCT, CAR-T, or other experimental treatments is recommended in patients with multiple relapses.</p>
      </sec>
      <sec id="article-132354.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnosis for relapsed and refractory follicular lymphoma include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Autoimmune disorders&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Chronic infections&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Reactive follicular hyperplasia</p>
          </list-item>
          <list-item>
            <p>Chronic lymphocytic leukemia/small lymphocytic lymphoma</p>
          </list-item>
          <list-item>
            <p>Diffuse large B-cell lymphoma&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Acute lymphoblastic lymphoma</p>
          </list-item>
          <list-item>
            <p>Marginal zone lymphoma</p>
          </list-item>
          <list-item>
            <p>Mucosa-associated lymphoid tissue (MALT) lymphoma</p>
          </list-item>
          <list-item>
            <p>Mantle cell lymphoma</p>
          </list-item>
          <list-item>
            <p>Lymphoplasmacytic lymphoma&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-132354.s10" sec-type="Radiation Oncology">
        <title>Radiation Oncology</title>
        <p>Radiation therapy can palliate symptoms in patients with localized symptoms associated with the follicular lymphoma affecting a single site. However, radiation has no role in the definitive management of relapsed follicular lymphoma.</p>
      </sec>
      <sec id="article-132354.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The clinical course of follicular lymphoma is variable. Some patients can have waxing and waning disease for years without needing treatment. Others with more disseminated disease and rapid tumor growth require therapy&#x000a0;due to organ dysfunction.&#x000a0;At the time of initial diagnosis, there are&#x000a0;2 widely used prognostic indices for follicular lymphoma: the follicular lymphoma international prognostic index (FLIPI)&#x000a0;and the PRIMA prognostic index (PRIMA-PI).<xref ref-type="bibr" rid="article-132354.r41">[41]</xref><xref ref-type="bibr" rid="article-132354.r42">[42]</xref>&#x000a0;FLIPI is based on&#x000a0;5 adverse prognostic factors (age &#x0003e;60 yrs, stage III or IV disease, Hemoglobin levels of &#x0003c;12 g/dL, number of involved nodal areas &#x0003e;4, and serum LDH greater than the upper limit of normal). PRIMA-PI score uses beta-2 microglobulin and bone marrow involvement to identify prognostic subgroups. Approximately 20 percent of patients have an aggressive disease course with short remission durations, frequent relapses, and shortened OS.</p>
        <p>At the time of relapse, the best predictor of tumor aggressiveness is the duration of remission following initial treatment.&#x000a0;Early treatment failure is defined as patients with follicular lymphoma progressing within 24 months (POD24) of initial immunochemotherapy or within 12 months of single-agent rituximab.&#x000a0;In addition, a&#x000a0;small group of follicular lymphoma patients undergo histologic transformation to more aggressive lymphomas. Patients with histologic transformation generally have a worse prognosis and require more aggressive therapy.</p>
      </sec>
      <sec id="article-132354.s12" sec-type="Complications">
        <title>Complications</title>
        <p>As mentioned above, about 20% of patients with follicular lymphoma have an aggressive course of disease with shorter remissions, frequent relapses, and reduced overall survival.</p>
      </sec>
      <sec id="article-132354.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be educated on the clinical course of relapsing and remitting follicular lymphomas and the available treatment options. Despite the slow-growing nature of follicular lymphoma, it is unknown whether current treatments can cure most cases. Patients should be informed of the potential complications, side effects, and toxicity of chemotherapy, immunotherapy, and stem cell transplantation, as well as the fact that most patients require several of these treatments over the course of follicular lymphoma management. Medication adherence and clinic follow-ups should be emphasized, as patients require close monitoring for potential treatment complications, response assessments, and recurrence evaluation.</p>
      </sec>
      <sec id="article-132354.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Follicular lymphoma is an indolent lymphoma with chronic and variable clinical course. Its optimal management requires an interprofessional approach involving a team of medical oncologists or hematologists, stem cell transplant physicians, radiation oncologists, primary care physicians, a palliative care team, psychiatrists, psychologists, infectious disease physicians, pharmacists, registered dieticians, social workers, and case managers. Interpersonal communication and updates regarding treatment plans can significantly alleviate patients' and patients' families' concerns and bring all care team members together. Because cancer diagnosis and recurrence frequently cause psychological distress, prompt identification and referral to a psychiatrist or psychologist can improve overall treatment adherence and outcomes. This interprofessional team approach yields optimal patient results.&#x000a0;</p>
      </sec>
      <sec id="article-132354.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=132354&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=132354">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/blood-disorders/relapsed-and-refractory-follicular-lymphoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=132354">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/132354/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=132354">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-132354.s16">
        <title>References</title>
        <ref id="article-132354.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casulo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Byrtek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Farber</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Flowers</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Hainsworth</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Cerhan</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Zelenetz</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Friedberg</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.</article-title>
            <source>J Clin Oncol</source>
            <year>2015</year>
            <month>Aug</month>
            <day>10</day>
            <volume>33</volume>
            <issue>23</issue>
            <fpage>2516</fpage>
            <page-range>2516-22</page-range>
            <pub-id pub-id-type="pmid">26124482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maurer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bachy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ghesqui&#x000e8;res</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ansell</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Nowakowski</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Inwards</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Allmer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chassagne-Cl&#x000e9;ment</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nicolas-Virelizier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sebban</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lebras</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sarkozy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Macon</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Syrbu</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Traverse-Glehan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Coiffier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Slager</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Witzig</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Habermann</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Salles</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cerhan</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.</article-title>
            <source>Am J Hematol</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>91</volume>
            <issue>11</issue>
            <fpage>1096</fpage>
            <page-range>1096-1101</page-range>
            <pub-id pub-id-type="pmid">27465588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cossman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Neckers</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Longo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>Low-grade lymphomas. Expression of developmentally regulated B-cell antigens.</article-title>
            <source>Am J Pathol</source>
            <year>1984</year>
            <month>Apr</month>
            <volume>115</volume>
            <issue>1</issue>
            <fpage>117</fpage>
            <page-range>117-24</page-range>
            <pub-id pub-id-type="pmid">6201073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ngan</surname>
                <given-names>BY</given-names>
              </name>
              <name>
                <surname>Chen-Levy</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Warnke</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Cleary</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation.</article-title>
            <source>N Engl J Med</source>
            <year>1988</year>
            <month>Jun</month>
            <day>23</day>
            <volume>318</volume>
            <issue>25</issue>
            <fpage>1638</fpage>
            <page-range>1638-44</page-range>
            <pub-id pub-id-type="pmid">3287162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morin</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Mendez-Lago</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mungall</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Goya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mungall</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Corbett</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Severson</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jackman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Krzywinski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Trinh</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Tamura-Wells</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Firme</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Rogic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Griffith</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yakovenko</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Smailus</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Moksa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chittaranjan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rimsza</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brooks-Wilson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Spinelli</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Ben-Neriah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Meissner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Woolcock</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Boyle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Delaney</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tse</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Butterfield</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Birol</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Holt</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Horsman</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Connors</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hirst</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gascoyne</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Marra</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.</article-title>
            <source>Nature</source>
            <year>2011</year>
            <month>Jul</month>
            <day>27</day>
            <volume>476</volume>
            <issue>7360</issue>
            <fpage>298</fpage>
            <page-range>298-303</page-range>
            <pub-id pub-id-type="pmid">21796119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pastore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jurinovic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kridel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hoster</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Staiger</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Szczepanowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pott</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Murakami</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Leich</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moccia</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Mottok</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sunkavalli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Van Hummelen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ducar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ennishi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shulha</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Hother</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Connors</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sehn</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Dreyling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Neuberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>M&#x000f6;ller</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Feller</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Hansmann</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rosenwald</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ott</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Klapper</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Unterhalt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hiddemann</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gascoyne</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Weinstock</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Weigert</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.</article-title>
            <source>Lancet Oncol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>1111</fpage>
            <page-range>1111-1122</page-range>
            <pub-id pub-id-type="pmid">26256760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pasqualucci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Trifonov</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fabbri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chiarenza</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Grunn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Messina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Elliot</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bhagat</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chadburn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gaidano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mullighan</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Rabadan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dalla-Favera</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Analysis of the coding genome of diffuse large B-cell lymphoma.</article-title>
            <source>Nat Genet</source>
            <year>2011</year>
            <month>Jul</month>
            <day>31</day>
            <volume>43</volume>
            <issue>9</issue>
            <fpage>830</fpage>
            <page-range>830-7</page-range>
            <pub-id pub-id-type="pmid">21804550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pasqualucci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dominguez-Sola</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chiarenza</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fabbri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Grunn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trifonov</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Lerach</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chadburn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murty</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Mullighan</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Gaidano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rabadan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brindle</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Dalla-Favera</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Inactivating mutations of acetyltransferase genes in B-cell lymphoma.</article-title>
            <source>Nature</source>
            <year>2011</year>
            <month>Mar</month>
            <day>10</day>
            <volume>471</volume>
            <issue>7337</issue>
            <fpage>189</fpage>
            <page-range>189-95</page-range>
            <pub-id pub-id-type="pmid">21390126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morin</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Severson</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Mungall</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>An</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Boyle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Woolcock</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Kuchenbauer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yap</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Humphries</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Griffith</surname>
                <given-names>OL</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kimbara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shashkin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Charlot</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Tcherpakov</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Corbett</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Varhol</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Smailus</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Moksa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Delaney</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Birol</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Schein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Holt</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Horsman</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Connors</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aparicio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hirst</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gascoyne</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Marra</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.</article-title>
            <source>Nat Genet</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>181</fpage>
            <page-range>181-5</page-range>
            <pub-id pub-id-type="pmid">20081860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sant</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Allemani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tereanu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>De Angelis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Capocaccia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Visser</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Marcos-Gragera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maynadi&#x000e9;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simonetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lutz</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Berrino</surname>
                <given-names>F</given-names>
              </name>
              <collab>HAEMACARE Working Group</collab>
            </person-group>
            <article-title>Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.</article-title>
            <source>Blood</source>
            <year>2010</year>
            <month>Nov</month>
            <day>11</day>
            <volume>116</volume>
            <issue>19</issue>
            <fpage>3724</fpage>
            <page-range>3724-34</page-range>
            <pub-id pub-id-type="pmid">20664057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morton</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Devesa</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hartge</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Weisenburger</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Linet</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.</article-title>
            <source>Blood</source>
            <year>2006</year>
            <month>Jan</month>
            <day>01</day>
            <volume>107</volume>
            <issue>1</issue>
            <fpage>265</fpage>
            <page-range>265-76</page-range>
            <pub-id pub-id-type="pmid">16150940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biagi</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Seymour</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation.</article-title>
            <source>Blood</source>
            <year>2002</year>
            <month>Jun</month>
            <day>15</day>
            <volume>99</volume>
            <issue>12</issue>
            <fpage>4265</fpage>
            <page-range>4265-75</page-range>
            <pub-id pub-id-type="pmid">12036852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shirley</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Sayeed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Finlayson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Incidence of haematological malignancies by ethnic group in England, 2001-7.</article-title>
            <source>Br J Haematol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>163</volume>
            <issue>4</issue>
            <fpage>465</fpage>
            <page-range>465-77</page-range>
            <pub-id pub-id-type="pmid">24033296</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laurini</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Boilesen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Diebold</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Maclennan</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller-Hermelink</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Nathwani</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Armitage</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Weisenburger</surname>
                <given-names>DD</given-names>
              </name>
            </person-group>
            <article-title>Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases.</article-title>
            <source>Blood</source>
            <year>2012</year>
            <month>Dec</month>
            <day>06</day>
            <volume>120</volume>
            <issue>24</issue>
            <fpage>4795</fpage>
            <page-range>4795-801</page-range>
            <pub-id pub-id-type="pmid">23086753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Junl&#x000e9;n</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kimby</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lockmer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lind&#x000e9;n</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Nilsson-Ehle</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Erlanson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hagberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>R&#x000e5;dlund</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hagberg</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Wahlin</surname>
                <given-names>BE</given-names>
              </name>
            </person-group>
            <article-title>Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study.</article-title>
            <source>Leukemia</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>668</fpage>
            <page-range>668-76</page-range>
            <pub-id pub-id-type="pmid">25151959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pinto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hutchison</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Trevenen</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Berard</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Follicular lymphomas in pediatric patients.</article-title>
            <source>Mod Pathol</source>
            <year>1990</year>
            <month>May</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>308</fpage>
            <page-range>308-13</page-range>
            <pub-id pub-id-type="pmid">2194214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Winberg</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Nathwani</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Bearman</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Rappaport</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Follicular (nodular) lymphoma during the first two decades of life: a clinicopathologic study of 12 patients.</article-title>
            <source>Cancer</source>
            <year>1981</year>
            <month>Nov</month>
            <day>15</day>
            <volume>48</volume>
            <issue>10</issue>
            <fpage>2223</fpage>
            <page-range>2223-35</page-range>
            <pub-id pub-id-type="pmid">7028244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frizzera</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Follicular (nodular) lymphoma in childhood: a rare clinical-pathological entity. Report of eight cases from four cancer centers.</article-title>
            <source>Cancer</source>
            <year>1979</year>
            <month>Dec</month>
            <volume>44</volume>
            <issue>6</issue>
            <fpage>2218</fpage>
            <page-range>2218-35</page-range>
            <pub-id pub-id-type="pmid">389411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Swerdlow</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Pileri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.</article-title>
            <source>Blood</source>
            <year>2011</year>
            <month>May</month>
            <day>12</day>
            <volume>117</volume>
            <issue>19</issue>
            <fpage>5019</fpage>
            <page-range>5019-32</page-range>
            <pub-id pub-id-type="pmid">21300984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karube</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Suzumiya</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sugita</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nomura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Komatani</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takeshita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kikuchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Takasu</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Arakawa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tagawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Seto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ohshima</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features.</article-title>
            <source>Blood</source>
            <year>2007</year>
            <month>Apr</month>
            <day>01</day>
            <volume>109</volume>
            <issue>7</issue>
            <fpage>3076</fpage>
            <page-range>3076-9</page-range>
            <pub-id pub-id-type="pmid">17138820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barry</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Kingma</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Sorbara</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Raffeld</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pittaluga</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>CD5+ follicular lymphoma: a clinicopathologic study of three cases.</article-title>
            <source>Am J Clin Pathol</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>118</volume>
            <issue>4</issue>
            <fpage>589</fpage>
            <page-range>589-98</page-range>
            <pub-id pub-id-type="pmid">12375647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flenghi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bigerna</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fizzotti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Venturi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pasqualucci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pileri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Gambacorta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pacini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Baroni</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Pescarmona</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Anagnostopoulos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Asdrubali</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Martelli</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Pelicci</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Dalla-Favera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Falini</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region.</article-title>
            <source>Am J Pathol</source>
            <year>1996</year>
            <month>May</month>
            <volume>148</volume>
            <issue>5</issue>
            <fpage>1543</fpage>
            <page-range>1543-55</page-range>
            <pub-id pub-id-type="pmid">8623923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pittaluga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ayoubi</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Wlodarska</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Stul</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cassiman</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Mecucci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Van Den Berghe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Van De Ven</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>De Wolf-Peeters</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>BCL-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin's lymphomas.</article-title>
            <source>J Pathol</source>
            <year>1996</year>
            <month>Jun</month>
            <volume>179</volume>
            <issue>2</issue>
            <fpage>145</fpage>
            <page-range>145-50</page-range>
            <pub-id pub-id-type="pmid">8758205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Weisenburger</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Ruby</surname>
                <given-names>EI</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Vose</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bierman</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Bast</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Daley</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Armitage</surname>
                <given-names>JO</given-names>
              </name>
            </person-group>
            <article-title>Prognostic value of cellular proliferation and histologic grade in follicular lymphoma.</article-title>
            <source>Blood</source>
            <year>1995</year>
            <month>Jun</month>
            <day>15</day>
            <volume>85</volume>
            <issue>12</issue>
            <fpage>3671</fpage>
            <page-range>3671-8</page-range>
            <pub-id pub-id-type="pmid">7780151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chabner</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Berard</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Garvin</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>DeVita</surname>
                <given-names>VT</given-names>
              </name>
            </person-group>
            <article-title>Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute.</article-title>
            <source>Cancer</source>
            <year>1982</year>
            <month>Dec</month>
            <day>15</day>
            <volume>50</volume>
            <issue>12</issue>
            <fpage>2699</fpage>
            <page-range>2699-707</page-range>
            <pub-id pub-id-type="pmid">7139563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casulo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Le-Rademacher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hoster</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hochster</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Hiddemann</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kimby</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Herold</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sebban</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gyan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Foon</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vitolo</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Salles</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Flowers</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.</article-title>
            <source>Blood</source>
            <year>2022</year>
            <month>Mar</month>
            <day>17</day>
            <volume>139</volume>
            <issue>11</issue>
            <fpage>1684</fpage>
            <page-range>1684-1693</page-range>
            <pub-id pub-id-type="pmid">34614146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Godfrey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>DiGilio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bachanova</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bacher</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Bashey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bola&#x000f1;os-Meade</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cairo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chhabra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Copelan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dahi</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Aljurf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Farooq</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Ganguly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hertzberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Holmberg</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Inwards</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kanate</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Karmali</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kenkre</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Kharfan-Dabaja</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lazarus</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Mei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mussetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nishihori</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ramakrishnan Geethakumari</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Savani</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Schouten</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Urbano-Ispizua</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vij</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vose</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sureda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hamadani</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure.</article-title>
            <source>Cancer</source>
            <year>2018</year>
            <month>Jun</month>
            <day>15</day>
            <volume>124</volume>
            <issue>12</issue>
            <fpage>2541</fpage>
            <page-range>2541-2551</page-range>
            <pub-id pub-id-type="pmid">29645093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casulo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Friedberg</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Flowers</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DiGilio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Inwards</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Aljurf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Choe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Copelan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Farooq</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Fenske</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Freytes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gaballa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ganguly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jethava</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kamble</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Kenkre</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Lazarus</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lazaryan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Rezvani</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Rizzieri</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Solh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sureda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>William</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cumpston</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zelenetz</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Hamadani</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis.</article-title>
            <source>Biol Blood Marrow Transplant</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>24</volume>
            <issue>6</issue>
            <fpage>1163</fpage>
            <page-range>1163-1171</page-range>
            <pub-id pub-id-type="pmid">29242111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jurinovic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Metzner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pfreundschuh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schmitz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wandt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Dreger</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dreyling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hiddemann</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Unterhalt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoster</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Weigert</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group.</article-title>
            <source>Biol Blood Marrow Transplant</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>24</volume>
            <issue>6</issue>
            <fpage>1172</fpage>
            <page-range>1172-1179</page-range>
            <pub-id pub-id-type="pmid">29605716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacobson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Chavez</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Sehgal</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>William</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Munoz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Salles</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Munshi</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Casulo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Maloney</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>de Vos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reshef</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Yakoub-Agha</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Oluwole</surname>
                <given-names>OO</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>HCH</given-names>
              </name>
              <name>
                <surname>Rosenblatt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Plaks</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Vezan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Avanzi</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Neelapu</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>91</fpage>
            <page-range>91-103</page-range>
            <pub-id pub-id-type="pmid">34895487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fowler</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Dickinson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dreyling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martinez-Lopez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kolstad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Popplewell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chavez</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Bachy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Harigae</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kersten</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Andreadis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Riedell</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-Sim&#x000f3;n</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Nastoupil</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>von Tresckow</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ferreri</surname>
                <given-names>AJM</given-names>
              </name>
              <name>
                <surname>Teshima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Patten</surname>
                <given-names>PEM</given-names>
              </name>
              <name>
                <surname>McGuirk</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Petzer</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Offner</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Viardot</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zinzani</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Malladi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Awasthi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Masood</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anak</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Schuster</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thieblemont</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.</article-title>
            <source>Nat Med</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>325</fpage>
            <page-range>325-332</page-range>
            <pub-id pub-id-type="pmid">34921238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahl</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Gascoyne</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Krauss</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Habermann</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Swinnen</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Schuster</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Sborov</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ehmann</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Horning</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.</article-title>
            <source>J Clin Oncol</source>
            <year>2014</year>
            <month>Oct</month>
            <day>01</day>
            <volume>32</volume>
            <issue>28</issue>
            <fpage>3096</fpage>
            <page-range>3096-102</page-range>
            <pub-id pub-id-type="pmid">25154829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martinelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schmitz</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Utiger</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Cerny</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Bassi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Okkinga</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stupp</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stahel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heizmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vorobiof</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lohri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dietrich</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ghielmini</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98.</article-title>
            <source>J Clin Oncol</source>
            <year>2010</year>
            <month>Oct</month>
            <day>10</day>
            <volume>28</volume>
            <issue>29</issue>
            <fpage>4480</fpage>
            <page-range>4480-4</page-range>
            <pub-id pub-id-type="pmid">20697092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maloney</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Ogura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fukuhara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lasher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Izquierdo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Banerjee</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tobinai</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy.</article-title>
            <source>Blood Adv</source>
            <year>2020</year>
            <month>Aug</month>
            <day>25</day>
            <volume>4</volume>
            <issue>16</issue>
            <fpage>3886</fpage>
            <page-range>3886-3893</page-range>
            <pub-id pub-id-type="pmid">32810220</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghielmini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schmitz</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Cogliatti</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Pichert</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hummerjohann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Waltzer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Fey</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Betticher</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Martinelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Peccatori</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stupp</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kovacsovics</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Helg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lohri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bargetzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vorobiof</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cerny</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.</article-title>
            <source>Blood</source>
            <year>2004</year>
            <month>Jun</month>
            <day>15</day>
            <volume>103</volume>
            <issue>12</issue>
            <fpage>4416</fpage>
            <page-range>4416-23</page-range>
            <pub-id pub-id-type="pmid">14976046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheson</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Chua</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dueck</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Trn&#x0011b;n&#x000fd;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bouabdallah</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Delwail</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Press</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Salles</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gribben</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Lennard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lugtenburg</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Fingerle-Rowson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mattiello</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Knapp</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sehn</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.</article-title>
            <source>J Clin Oncol</source>
            <year>2018</year>
            <month>Aug</month>
            <day>01</day>
            <volume>36</volume>
            <issue>22</issue>
            <fpage>2259</fpage>
            <page-range>2259-2266</page-range>
            <pub-id pub-id-type="pmid">29584548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vidal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gafter-Gvili</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salles</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dreyling</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Ghielmini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hsu Schmitz</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Pettengell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Witzens-Harig</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shpilberg</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2011</year>
            <month>Dec</month>
            <day>07</day>
            <volume>103</volume>
            <issue>23</issue>
            <fpage>1799</fpage>
            <page-range>1799-806</page-range>
            <pub-id pub-id-type="pmid">22021664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morschhauser</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tilly</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chaidos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McKay</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Assouline</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Batlevi</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ribrag</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Damaj</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Dickinson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jurczak</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kazmierczak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Opat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Radford</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Whalen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Adib</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Salles</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>11</issue>
            <fpage>1433</fpage>
            <page-range>1433-1442</page-range>
            <pub-id pub-id-type="pmid">33035457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leonard</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Trneny</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Izutsu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Offner</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Scheliga</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nowakowski</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Re</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fogliatto</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Scheinberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Flinn</surname>
                <given-names>IW</given-names>
              </name>
              <name>
                <surname>Moreira</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cabe&#x000e7;adas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kalambakas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fustier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gribben</surname>
                <given-names>JG</given-names>
              </name>
              <collab>AUGMENT Trial Investigators</collab>
            </person-group>
            <article-title>AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.</article-title>
            <source>J Clin Oncol</source>
            <year>2019</year>
            <month>May</month>
            <day>10</day>
            <volume>37</volume>
            <issue>14</issue>
            <fpage>1188</fpage>
            <page-range>1188-1199</page-range>
            <pub-id pub-id-type="pmid">30897038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matasar</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Capra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x000d6;zcan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ya&#x000f1;ez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sapunarova</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jurczak</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hamed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bondarenko</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Geissler</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lazaroiu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saydam</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Szomor</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Bouabdallah</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Galiulin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Uchida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Soler</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hiemeyer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mehra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Childs</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zinzani</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2021</year>
            <month>May</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>678</fpage>
            <page-range>678-689</page-range>
            <pub-id pub-id-type="pmid">33848462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solal-C&#x000e9;ligny</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cahu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Cartron</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful?</article-title>
            <source>Int J Hematol</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>92</volume>
            <issue>2</issue>
            <fpage>246</fpage>
            <page-range>246-54</page-range>
            <pub-id pub-id-type="pmid">20803352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132354.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Federico</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bellei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marcheselli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Luminari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lopez-Guillermo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vitolo</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Pro</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pileri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pulsoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soubeyran</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cortelazzo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Martinelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Martelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rigacci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Arcaini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Di Raimondo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Merli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sabattini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Solal-C&#x000e9;ligny</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.</article-title>
            <source>J Clin Oncol</source>
            <year>2009</year>
            <month>Sep</month>
            <day>20</day>
            <volume>27</volume>
            <issue>27</issue>
            <fpage>4555</fpage>
            <page-range>4555-62</page-range>
            <pub-id pub-id-type="pmid">19652063</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
